CLINICAL_TRIALS
trial_result
· 2022-09-21
Clinical Trial Update: A Study of PRN1008 in Patients With Pemphigus [Phase 3]
Summary
Phase 3 study of PRN1008 in pemphigus was terminated; results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Principia Biopharma, a Sanofi Company | Conditions: Pemphigus | Phase 3 | Status: TERMINATED | Results posted: 2022-09-21